Dharminder Chauhan

Dharminder Chauhan

Auto-generated profile, based on publicly available information

Dharminder Chauhan

The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2012 in Cancer Cell
Verified
Journal Article
Closed access
DCDharminder Chauhan
Dharminder Chauhan
ZTZe Tian
Ze Tian
BNBenjamin Nicholson
Benjamin Nicholson
KKK.G. Suresh Kumar
K.G. Suresh Kumar
BZBin Zhou
Bin Zhou
KAKenneth Anderson
Kenneth Anderson

14 August 2011 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
DCDharminder Chauhan
Dharminder Chauhan
ZTZe Tian
Ze Tian
BZBin Zhou
Bin Zhou
DKDeborah Kuhn
Deborah Kuhn
RORobert Zygmunt Orlowski
Robert Zygmunt Orlowski
KAKenneth Anderson
Kenneth Anderson
Purpose: The success of bortezomib therapy for treatment of multiple myeloma (MM) led to the development of structurally and pharmacologically distinct novel proteasome inhibitors. In the present study, we evaluated the efficacy of one such novel orally bioactive proteasome inhibitor MLN9708/MLN2238 in MM using well-established in vitro and in vivo models. Experimental Design: MM cell lines, primary patient cells, and the human MM xenograft animal model were used to study the antitumor activity of MN2238. Results: Treatment of MM cells with MLN2238 predominantly inhibits chymotrypsin-like activity of the proteasome and induces accumulation of ubiquitinated proteins. MLN2238 inhibits growth and induces apoptosis in MM cells resistant to conventional and bortezomib therapies without affecting the viability of normal cells. In animal tumor model studies, MLN2238 is well tolerated and inhibits tumor growth with significantly reduced tumor recurrence. A head-to-head analysis of MLN2238 versus bortezomib showed a significantly longer survival time in mice treated with MLN2238 than mice receiving bortezomib. Immununostaining of MM tumors from MLN2238-treated mice showed growth inhibition, apoptosis, and a decrease in associated angiogenesis. Mechanistic studies showed that MLN2238-triggered apoptosis is associated with activation of caspase-3, caspase-8, and caspase-9; increase in p53, p21, NOXA, PUMA, and E2F; induction of endoplasmic reticulum (ER) stress response proteins Bip, phospho-eIF2-α, and CHOP; and inhibition of nuclear factor kappa B. Finally, combining MLN2238 with lenalidomide, histone deacetylase inhibitor suberoylanilide hydroxamic acid, or dexamethasone triggers synergistic anti-MM activity. Conclusion: Our preclinical study supports clinical evaluation of MLN9708, alone or in combination, as a potential MM therapy. Clin Cancer Res; 17(16); 5311–21. ©2011 AACR.

30 January 2014 in Blood
Verified
Journal Article
Open access
PDF file
ZTZe Tian
Ze Tian
PDPádraig D'Arcy
Pádraig D'Arcy
XWXin Wang
Xin Wang
ARArghya Ray
Arghya Ray
YTYu-Tzu Tai
Yu-Tzu Tai
KAKenneth C. Anderson
Kenneth C. Anderson
Key Points: Deubiquitylating enzymes USP14 and UCHL5 are involved in the tumorigenesis of MM. b-AP15 is a specific USP14 and UCHL5 inhibitor, which blocks growth and induces apoptosis in MM cells.

1 October 2009 in Cancer Cell
Verified
Journal Article
Closed access
DCDharminder Chauhan
Dharminder Chauhan
ASAjita V. Singh
Ajita V. Singh
MBMohan Brahmandam
Mohan Brahmandam
RCRuben Carrasco
Ruben Carrasco
MBMadhavi Bandi
Madhavi Bandi
KAKenneth Anderson
Kenneth Anderson

30 January 2015 in Leukemia
Verified
Journal Article
Closed access
PDF file
ARA Ray
A Ray
DDD S Das
D S Das
YSY Song
Y Song
PRP Richardson
P Richardson
NMN C Munshi
N C Munshi
KAKenneth Anderson
Kenneth Anderson

2 December 2010 in Blood
Verified
Journal Article
Closed access
PDF file
DCDharminder Chauhan
Dharminder Chauhan
ASAjita V. Singh
Ajita V. Singh
MAMonette Aujay
Monette Aujay
CKChristopher J. Kirk
Christopher J. Kirk
MBMadhavi Bandi
Madhavi Bandi
KAKenneth C. Anderson
Kenneth C. Anderson
Bortezomib therapy has proven successful for the treatment of relapsed, relapsed/refractory, and newly diagnosed multiple myeloma (MM). At present, bortezomib is available as an intravenous injection, and its prolonged treatment is associated with toxicity and development of drug resistance. Here we show that the novel proteasome inhibitor ONX 0912, a tripeptide epoxyketone, inhibits growth and induces apoptosis in MM cells resistant to conventional and bortezomib therapies. The anti-MM activity of ONX-0912 is associated with activation of caspase-8, caspase-9, caspase-3, and poly(ADP) ribose polymerase, as well as inhibition of migration of MM cells and angiogenesis. ONX 0912, like bortezomib, predominantly inhibits chymotrypsin-like activity of the proteasome and is distinct from bortezomib in its chemical structure. Importantly, ONX 0912 is orally bioactive. In animal tumor model studies, ONX 0912 significantly reduced tumor progression and prolonged survival. Immununostaining of MM tumors from ONX 0912–treated mice showed growth inhibition, apoptosis, and a decrease in associated angiogenesis. Finally, ONX 0912 enhances anti-MM activity of bortezomib, lenalidomide dexamethasone, or pan-histone deacetylase inhibitor. Taken together, our study provides the rationale for clinical protocols evaluating ONX 0912, either alone or in combination, to improve patient outcome in MM.